1. Home
  2. SONO vs ZYME Comparison

SONO vs ZYME Comparison

Compare SONO & ZYME Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Sonos Inc.

SONO

Sonos Inc.

HOLD

Current Price

$14.69

Market Cap

1.8B

ML Signal

HOLD

Logo Zymeworks Inc.

ZYME

Zymeworks Inc.

HOLD

Current Price

$22.86

Market Cap

1.7B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
SONO
ZYME
Founded
2002
2003
Country
United States
United States
Employees
N/A
N/A
Industry
Consumer Electronics/Video Chains
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
1.8B
1.7B
IPO Year
2018
2022

Fundamental Metrics

Financial Performance
Metric
SONO
ZYME
Price
$14.69
$22.86
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
3
11
Target Price
$19.67
$38.90
AVG Volume (30 Days)
2.2M
531.8K
Earning Date
05-04-2026
05-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
33.33
EPS
0.52
N/A
Revenue
$1,443,276,000.00
$105,965,000.00
Revenue This Year
$5.04
$183.10
Revenue Next Year
$6.53
N/A
P/E Ratio
$27.94
N/A
Revenue Growth
N/A
38.87
52 Week Low
$10.12
$11.86
52 Week High
$19.82
$29.75

Technical Indicators

Market Signals
Indicator
SONO
ZYME
Relative Strength Index (RSI) 52.31 36.89
Support Level $12.77 $22.20
Resistance Level $15.35 $23.66
Average True Range (ATR) 0.70 0.92
MACD 0.08 -0.30
Stochastic Oscillator 48.76 1.07

Price Performance

Historical Comparison
SONO
ZYME

About SONO Sonos Inc.

Sonos Inc is an audio company dedicated to elevating life through sound, offering a connected platform that brings together music, movies, stories, and conversations. Its portfolio includes home theater speakers, components, plug-in and portable speakers and headphones, known for exceptional sound, thoughtful design, ease of use and seamless access to audio content. Its partner products and other revenue categories include accessories for home integration, such as custom-designed stands, mounts, and shelving units, along with partnerships for architectural speakers and automotive sound systems, as well as licensing, advertising revenue, and subscription-based services. The company operates in the United States and other countries, with the majority of revenue coming from the United States.

About ZYME Zymeworks Inc.

Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.

Share on Social Networks: